SNS-595
Potential for Advanced Hematologic and Solid Malignancies
SNS-595 is a replication-dependent DNA-damaging agent that induces an irreversible G2 arrest and apoptosis. As a result, cancer cells, which are typically proliferative and resistant to pathways that eliminate damaged or aberrant cells, no longer divide and die. SNS-595 acts synergistically in cancer cell lines when combined with several standard chemotherapeutic agents in vitro.
In preclinical models, SNS-595 shows promising in vivo activity when combined with Ara— C, cytarabine, gemcitabine, cisplatin, and carboplatin. Additional rational combinations with SNS-595 are currently under investigation.
SNS-595 is in clinical studies of acute leukemias and platinum-resistant ovarian cancer. Clinical responses with single agent SNS-595 have been seen in these indications, as well as in non-small cell and small cell lung cancers. SNS-595 has the potential for activity as a single agent and, based on our current understanding of mechanism of action, in rational combination with other anti-cancer agents for the treatment of both advanced and earlier stage disease.
SNS-595 Presentations
Phase 2 Study of Voreloxin (SNS-595) as Single Agent Therapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia (AML): Preliminary Safety and Clinical ResponsesVoreloxin in Combination with Cytarabine Demonstrates Preliminary Clinical Responses in a Phase 1b/2 Study In Relapsed/Refractory Acute Myeloid LeukemiaVoreloxin (SNS-595) in Platinum-Resistant Ovarian Cancer
